Related Experiment Video

Updated: Nov 23, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.9K

Pharmacological Inhibition of mTORC2 Reduces Migration and Metastasis in Melanoma

Jessica Guenzle1, Harue Akasaka1, Katharina Joechle1

  • 1Department of General and Visceral Surgery, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Strasse 55, 79106 Freiburg, Germany.

International Journal of Molecular Sciences
|December 30, 2020
PubMed

Insights

Targeting the mTORC2 pathway with JR-AB2-011 significantly reduces melanoma liver metastasis. This novel approach inhibits cell migration, invasion, and proliferation, offering a promising new treatment strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Metastasis Research

Background:

  • Liver metastasis in melanoma patients carries a poor prognosis despite therapeutic advancements.
  • The mTOR signaling pathway is a known target for anti-cancer activity, but specific roles of mTORC2 in melanoma liver metastasis remain unclear.

Purpose of the Study:

  • To investigate the impact of specific mTORC2 inhibition on melanoma cell behavior and liver metastasis.
  • To evaluate the efficacy of the novel mTORC2 inhibitor JR-AB2-011 in preclinical models of melanoma liver metastasis.

Main Methods:

  • Utilized the specific mTORC2 inhibitor JR-AB2-011 in melanoma cell lines.
  • Assessed cell migration, invasion, MMP2 activation, proliferation, and cell death pathways.
  • Employed a syngeneic murine model for in vivo evaluation of liver metastasis reduction using JR-AB2-011, confirmed by in vivo imaging and necropsy.

Main Results:

  • JR-AB2-011 significantly reduced melanoma cell migration and invasion by impairing MMP2 activation.
  • mTORC2 blockade induced non-apoptotic cell death and dose-dependent reduction in tumor cell proliferation.
  • Therapy with JR-AB2-011 led to a significant decrease in liver metastasis in a murine model.

Conclusions:

  • Pharmacological blockade of mTORC2 using JR-AB2-011 demonstrates potent anti-cancer activity against melanoma liver metastasis.
  • This study establishes mTORC2 inhibition as a promising novel therapeutic strategy for managing melanoma liver metastasis.
Keywords:
mTORC2melanomametastasismigration

More Related Videos

A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.3K
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.7K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.4K
Cell Polarization by Rho Proteins01:21

Cell Polarization by Rho Proteins

Cell polarity is the asymmetric distribution of cellular and membrane components, making one side of the cell different from the other. This polarity is essential to many processes such as embryogenesis, axon migration, glucose transport across epithelial cells, and directional cell migration. A migrating cell responds to intracellular or extracellular signals via molecular cascades that reorganize the actin cytoskeleton to establish this polarity. In these cells, the Rho family proteins Cdc42,...
3.3K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.9K